TIDMEVG

RNS Number : 0759G

Evgen Pharma PLC

23 November 2020

Evgen Pharma plc

("Evgen" or the "Company")

Recruitment of first patient in STAR trial

Evaluation of SFX-01 in acute respiratory distress syndrome commences

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that, the first patient has now been enrolled and dosed in the STAR trial (SFX-01 treatment for Acute Respiratory Infections).

This Phase II/III trial is a randomised, placebo-controlled trial and is sponsored by the University of Dundee. It will investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") in patients with community-acquired pneumonia who have been or are being tested for suspected COVID-19. Patients may therefore present with COVID-19 or other respiratory diseases.

SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. Preclinical studies have shown that up-regulating the Nrf2 pathway reduces the severity of ARDS, the progressive lung damage observed in COVID-19 and pneumonia patients, which can result in the need for invasive ventilation in an intensive care unit.

Dr Huw Jones, CEO of Evgen, commented: "The initiation of enrolment is an important milestone for us and marks the first use of SFX-01 in respiratory disease, targeting the Nrf2 pathway. We remain hopeful that the outcome of this trial will reduce both the severity and duration of the disease for COVID-19 patients and those with pneumonia from other infective agents."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Enquiries:

 
 Evgen Pharma plc www.evgen.com                                         via Walbrook 
 Barry Clare, Chairman 
  Dr Huw Jones, CEO 
 Richard Moulson, CFO 
 
 finnCap www.finncap.com                                         +44 (0)20 7220 0500 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane (ECM) 
 
 Walbrook PR                              +44 (0)20 7933 878 or evgen@walbrookpr.com 
                                                   +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                  741 001

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RESPPGAUGUPUGMU

(END) Dow Jones Newswires

November 23, 2020 02:00 ET (07:00 GMT)

Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Evgen Pharma Charts.
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Evgen Pharma Charts.